Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.

M Dietel; N Savelov; R Salanova; P Micke; G Bigras; T Hida; J Antunez; B Guldhammer Skov; Georg Hutarew; L F Sua; H Akita; O S H Chan; B Piperdi; T Burke; S Khambata-Ford; A C Deitz

doi:10.1016/j.lungcan.2019.06.012

Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.

M Dietel, N Savelov, R Salanova, P Micke, G Bigras, T Hida, J Antunez, B Guldhammer Skov, Georg Hutarew (Co-author), L F Sua, H Akita, O S H Chan, B Piperdi, T Burke, S Khambata-Ford, A C Deitz

Institute of Pathology

Research output: Contribution to journal › Original Article › peer-review

100 Citations (Web of Science)

Original language	English
Pages (from-to)	174-179
Journal	LUNG CANCER
Volume	134
DOIs	https://doi.org/10.1016/j.lungcan.2019.06.012
Publication status	Published - 2019

Keywords

PEMBROLIZUMAB
THERAPY
ASSAYS

Access to Document

10.1016/j.lungcan.2019.06.012

Cite this

Dietel, M., Savelov, N., Salanova, R., Micke, P., Bigras, G., Hida, T., Antunez, J., Guldhammer Skov, B., Hutarew, G., Sua, L. F., Akita, H., Chan, O. S. H., Piperdi, B., Burke, T., Khambata-Ford, S., & Deitz, A. C. (2019). Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study. LUNG CANCER , 134, 174-179. https://doi.org/10.1016/j.lungcan.2019.06.012

@article{5f3f4e1d10e9430095e291c43356de0b,

title = "Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.",

keywords = "PEMBROLIZUMAB, THERAPY, ASSAYS",

author = "M Dietel and N Savelov and R Salanova and P Micke and G Bigras and T Hida and J Antunez and {Guldhammer Skov}, B and Georg Hutarew and Sua, {L F} and H Akita and Chan, {O S H} and B Piperdi and T Burke and S Khambata-Ford and Deitz, {A C}",

note = "Hutarew: Institute of Pathology, University Hospital and Paracelsus Medical University Salzburg, Salzburg, Austria",

year = "2019",

doi = "10.1016/j.lungcan.2019.06.012",

language = "English",

volume = "134",

pages = "174--179",

journal = "LUNG CANCER ",

issn = "0169-5002",

publisher = "Elsevier ",

}

Dietel, M, Savelov, N, Salanova, R, Micke, P, Bigras, G, Hida, T, Antunez, J, Guldhammer Skov, B, Hutarew, G, Sua, LF, Akita, H, Chan, OSH, Piperdi, B, Burke, T, Khambata-Ford, S & Deitz, AC 2019, 'Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.', LUNG CANCER , vol. 134, pp. 174-179. https://doi.org/10.1016/j.lungcan.2019.06.012

TY - JOUR

T1 - Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.

AU - Dietel, M

AU - Savelov, N

AU - Salanova, R

AU - Micke, P

AU - Bigras, G

AU - Hida, T

AU - Antunez, J

AU - Guldhammer Skov, B

AU - Hutarew, Georg

AU - Sua, L F

AU - Akita, H

AU - Chan, O S H

AU - Piperdi, B

AU - Burke, T

AU - Khambata-Ford, S

AU - Deitz, A C

N1 - Hutarew: Institute of Pathology, University Hospital and Paracelsus Medical University Salzburg, Salzburg, Austria

PY - 2019

Y1 - 2019

KW - PEMBROLIZUMAB

KW - THERAPY

KW - ASSAYS

U2 - 10.1016/j.lungcan.2019.06.012

DO - 10.1016/j.lungcan.2019.06.012

M3 - Original Article

C2 - 31319978

SN - 0169-5002

VL - 134

SP - 174

EP - 179

JO - LUNG CANCER

JF - LUNG CANCER

ER -